Salcaprozate sodium (SNAC) is an intestinal permeation enhancer that is used in drug formulations particularly for macromolecules and poorly permeable compounds. SNAC has been used in formulations of drugs that have undergone clinical trials and has achieved measurable increases in systemic exposure for certain peptides and small proteins when administered orally. Chemically it is an amphiphilic sodium salt that combines a salicylate moiety with a medium chain aliphatic segment, giving water solubility together with membrane-interacting properties. Mechanistically SNAC facilitates absorption primarily by promoting transcellular transport through reversible modulation of local membrane permeability and transient alteration of microenvironmental pH and lipophilicity, and by forming noncovalent associations with macromolecular APIs that can reduce proteolytic degradation. SNAC is compatible with typical solid oral dosage form processes, is amenable to standard analytical control by HPLC, NMR and MS, and its effect is concentration and formulation dependent so that dose, buffering and excipient selection are key variables in development.
Parent: Salcaprozate / Salcaprozic Acid
Parent: Salcaprozate
Parent: Salcaprozate Sodium
Parent: Salcaprozate/ Salcaprozic Acid
Typical quality specifications used during development and in commercial supply control for salcaprozate sodium are focused on high assay purity and low levels of related substances and elemental impurities. A representative specification framework is assay by HPLC greater than or equal to 98.0 percent, individual related compounds generally limited to 0.5 percent or less, and total related substances limited to 1.5 percent or less. Known related compounds include hydrolytic cleavage products such as the corresponding salicylic acid derivative and aliphatic acid fragments; individual concentrations of these hydrolysis and process-related impurities are commonly expected below 0.5 percent each under routine storage and handling. Residual solvents are controlled to ICH Q3C limits and elemental impurities are controlled to ICH Q3D guidance, with heavy metals typically specified at low ppm levels consistent with regulatory expectations. Water content and microbial specification are set according to intended use and packaging; final, product-specific limits should be established by the manufacturer and verified by validated analytical methods.
Salcaprozate sodium is used as an excipient to enhance oral absorption of poorly permeable drugs, especially peptides and other macromolecules. It is incorporated into formulations to increase transcellular uptake, reduce enzymatic loss in the lumen, and improve overall systemic exposure in a formulation dependent manner.
SNAC is used to enable or improve oral delivery of APIs with limited passive permeability. It is applied in formulation development to increase the fraction of dose absorbed, allow lower therapeutic dose strengths, and to enable oral administration of APIs that otherwise require parenteral routes.
SNAC is not a conventional surfactant. It is an amphiphilic small molecule that can show some surface activity at higher concentrations but its primary function as used in formulations is permeation enhancement through reversible modification of membrane interactions and local microenvironmental conditions rather than bulk surfactant-mediated solubilization.
Intestinal permeation enhancers are excipients that transiently increase intestinal absorption of large or poorly permeable molecules by one or more mechanisms such as opening paracellular pathways, increasing transcellular transport, altering membrane fluidity, or protecting APIs from enzymatic degradation. Selection requires balancing efficacy and safety, control of local exposure, reversible action, and compatibility with the API and dosage form. Examples include small amphiphiles like SNAC, medium chain fatty acids, and certain bile salt derivatives, each with distinct mechanism and formulation considerations.
